Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
Search
New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate)
New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate)
Office Hours Program | Partnering
Click here to find out how Boehringer Ingelheim's pioneering ‘Office Hours’ program has now mentored over 250 early-stage companies since 2015.
COPD_Patient_brochure.pdf
The BI Cares Patient Assistance Program - Editable Form
The BI Cares Patient Assistance Program - Gilotrif® - Fillable Form
The BI Cares Patient Assistance Program - Ofev® - Fillable Form
The BI Cares Patient Assistance Program
The BI Cares Patient Assistance Program - Gilotrif®
The BI Cares Patient Assistance Program - Ofev®
Patient information
Patient-centric cardio-renal-metabolic disease research at Boehringer Ingelheim
Patient Assistance Program Application form - Spanish
Patient Assistance Program Gilotrif Application editable form - Spanish
Patient Assistance Program Gilotrif Application form - Spanish
Patient Assistance Program Ofev Application editable form - Spanish
Patient Assistance Program Ofev Application form - Spanish
Full data announced in phase III EMPA-KIDNEY trial
The EMPA-KIDNEY phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD)
Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches
Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches
Our forward-looking approach drives breakthroughs
Our purpose is the patient—so our actions are those of a partner, our vision is always long-term, and our results are measured in lives changed and lives saved.
Boehringer Ingelheim Office Hours
Boehringer Ingelheim Office Hours
Our Curiosity Never Stops | Boehringer Ingelheim US
Hear from Dr. Cornelia Dorner-Ciossek on how brain research informs treatment methods for patients suffering with mental illnesses.
Clinical Trials
Boehringer Ingelheim is committed to advancing the discovery of new medicines through clinical trials.
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
Imprint
Here you can access contact details and information about Boehringer Ingelheim